Pharmaceuticals, Biotechnology and Life Sciences
Ironwood Pharmaceuticals and Allergan have won U.S. Food and Drug Administration’s (FDA) approval for 72 mcg dose of Linzess (linaclotide) for the treatment of chronic idiopathic constipation (CIC) in adult patients.
AstraZeneca’s Symbicort Inhalation Aerosol is going to be available for 6-12 years old children with asthma in the US
Johnson & Johnson said on Wednesday it will buy a Switzerland-based pharmaceutical company Actelion for $30 billion.
Ablynx and Merck KGaA (Germany) have reported encouraging results from a study in psoriasis patients with the bi-specific Nanobody anti-IL-17A/F (M1095), via a clinical trials website (https://clinicaltrials.gov/NCT02156466).
ImmuPharma has provided details of patient recruitment into its pivotal 52-week Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough compound for Lupus.
Beximco Pharmaceuticals has went overseas to form a joint venture (JV) with a Malaysia-based BioCare Manufacturing. This is the Bangladesh’s company’s first such JV.
Neovacs’s Scientific Advisory Board has recommended extension of the development of IFN Kinoid to a new indication, Type 1 Diabetes, with the objectives of obtaining preclinical proof of concept in 2017 and initiating clinical development for this program in the first half of 2018.
Novartis delivered a solid performance in 2016, absorbing Gleevec US loss of exclusivity while investing in key launches and the Alcon Division turnaround
The deal InnovaDerma had with PROS International Company of Korea to sell InnovaDerma products in a terrotiroy of S Korea, Japan, China and Russia has breaken apart, the UK based maker of hair and skin care products said on Wednesday.
Horizon Discovery Group expects to see 2016 revenues rise for about 20%, as it expects revenue of at least £24.0 million.